Pathways & interactions
Literature: 3'5'-cyclic nucleotide phosphodiesterase, catalytic domain (IPR002073)
References used in this entry
The following publications were referred to in the abstract:
Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Stone WM, Demaerschalk BM, Fowl RJ, Money SR.
17 129-33 2008
PMID: 18436153 Related citations
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
17 811-8 2008
PMID: 18447606 Related citations
Phosphodiesterase 5 inhibition in essential hypertension.
Ghiadoni L, Versari D, Taddei S.
Curr. Hypertens. Rep. 10 52-7 2008
PMID: 18367027 Related citations
The following publications were not referred to in the abstract, but provide useful additional information:
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS.
Proc. Natl. Acad. Sci. U.S.A. 105 13309-14 2008
PMID: 18757755 Related citations
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
Chen G, Wang H, Robinson H, Cai J, Wan Y, Ke H.
Biochem. Pharmacol. 75 1717-28 2008
PMID: 18346713 Related citations
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
Wang H, Ye M, Robinson H, Francis SH, Ke H.
Mol. Pharmacol. 73 104-10 2008
PMID: 17959709 Related citations
Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, Cai J, Ke H.
Biochem. J. 408 193-201 2007
PMID: 17727341 Related citations
The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10.
Wang H, Robinson H, Ke H.
J. Mol. Biol. 371 302-7 2007
PMID: 17582435 Related citations